Belzer UW® Cold Storage Solution
Proven solutions. Purposeful innovation. Uncompromising quality.
Belzer UW® Cold
Storage Solution
Proven solutions. Purposeful innovation. Uncompromising quality.
Committed Partner to the Transplant Community
Supply Agreements in Place with Multiple US Based Manufacturers
Minimum Inventory Levels of 60 days Assured to Protect from Shortages
Aseptically Manufactured in the US Using High Quality Bags to Prevent Product Failure in Critical Situations
Peelable Barcode Stickers – Saves Time and Avoids Errors
Advancing the Standard of Organ Preservation
Description
Belzer UW® Cold Storage Solution is a sterile non-pyrogenic solution with approximate calculations as follows:
- Osmolarity of 320mOsm
- Sodium concentration of 29 mEq/L
- Potassium concentration of 125 mEq/L
- pH of 7.4 at 20° C
Supplied
1,000 mL in one-liter bags, shelf carton of 10
2,000 mL in two-liter bags, shelf carton of 5
Storage
Store Belzer UW® Cold Storage Solution at temperatures between 2°–25°C (36°–77°F). Avoid excessive heat. Do not freeze the solution, and do not use if frozen. Do not use if discolored or if obvious particulate matter, precipitates, or contamination are evident in the solution.
Usage
Belzer UW® Cold Storage Solution is intended for in vitro flushing and cold storage of kidney, liver and pancreas organs at the time of their removal from the organ donor in preparation for storage, transportation and eventual transplantation into a donor recipient
- Excellent for living donor programs
- Less waste
- Saves time and money
Enables Storage at Room Temperature
Eliminates Refrigeration Concerns Required for ViaSpan® Solution
Belzer UW® Cold Storage Solution is manufactured in the USA.
Product Literature
Wisconsin Alumni
Research Foundation
Follow WARF on LinkedIn.
Bridge to Life is honored to be a licensee of the Wisconsin Alumni Research Foundation (“WARF”). Bridge to Life is the exclusive licensee of WARF’s trademark, Belzer UW®.
The Wisconsin Alumni Research Foundation’s mission is to support scientific research at the University of Wisconsin-Madison. WARF accomplishes this by:
- Moving inventions arising from the university’s laboratories to the marketplace for the benefit of the university, the inventors and society
- Carefully managing an endowment that WARF has grown since its inception
Nearly all of the income from WARF’s transfer of technology and investment management is returned each year to the university to fund further scientific research.
Bridge to Life™ is designated as a WARF Startup Company. In addition to providing Bridge to Life™ various licenses, WARF also owns 5% of the total shares of Bridge to Life™, the first time that WARF has taken an equity position in a startup company.
Learn more about the vital role WARF plays in the development of science and its implementation into tomorrow’s technology - www.warf.org
